Arielis Rodriguez Ulloa

Title: Arielis Rodriguez Ulloa: Innovator in Cancer Treatment

Introduction

Arielis Rodriguez Ulloa is a prominent inventor based in La Habana, Cuba. She has made significant contributions to the field of cancer treatment through her innovative research and development of pharmaceutical combinations aimed at improving therapeutic outcomes for patients with refractory tumors.

Latest Patents

Arielis holds a patent for a pharmaceutical combination designed for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs. This invention involves a Casein kinase 2 (CK2) peptide inhibitor, known as P15, which is used in conjunction with standard chemotherapeutic drugs. The combination allows for a more effective treatment regimen, achieving a concentration of cytostatic drugs that is 10- to 100-fold lower than when used alone. This innovative approach not only enhances the efficacy of the treatment but also reduces toxicity, making it a crucial advancement in cancer therapy.

Career Highlights

Arielis is affiliated with the Centro de Ingeniería Genética y Biotecnología, where she continues to work on groundbreaking research in biotechnology and pharmacology. Her dedication to improving cancer treatment options has positioned her as a key figure in her field.

Collaborations

Arielis collaborates with esteemed colleagues such as Silvio Ernesto Perea Rodriguez and Yasser Perera Negrin, contributing to a dynamic research environment focused on innovative solutions for cancer treatment.

Conclusion

Arielis Rodriguez Ulloa's work exemplifies the impact of innovation in the medical field, particularly in the fight against cancer. Her patented pharmaceutical combination represents a significant step forward in enhancing treatment efficacy while minimizing side effects.